Phaseline

Targets › ALAD

ALAD (Delta-aminolevulinic acid dehydratase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2026.

Catalyzes an early step in the biosynthesis of tetrapyrroles. Binds two molecules of 5-aminolevulinate per subunit, each at a distinct site, and catalyzes their condensation to form porphobilinogen. (UniProt, P13716)

Open in Phaseline: the race on ALAD, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
michal roll5-AMINOLEVULINIC ACID (5-ALA)
Prodrug metabolized to protoporphyrin IX for photodynamic therapy
ALADPhase 2The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as anDec 2026

Conditions

The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an (1)

Modalities

small molecule (1)

Companies

michal roll (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.